参考文献/References:
[1]Aiman W,Rayi A.Low Grade Gliomas[EB/OL].https://www.ncbi.nlm.nih.gov/books/NBK560668/,2022-05-15/2022-07-11.[2]Louis DN,Perry A,Wesseling P,et al.The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J].Neuro Oncol,2021,23(8):1231-1251.[3]Wang TJC,Mehta MP.Low-Grade Glioma Radiotherapy Treatment and Trials[J].Neurosurg Clin N Am,2019,30(1):111-118.[4]Fei L,Ren X,Yu H,et al.Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?[J].Frontiers in Immunology,2021,12:771210.[5]Matsushima K,Larsen CG,Dubois GC,et al.Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line[J].J Exp Med,1989,169(4):1485-1490.[6]Chiang Y,Tsai YC,Wang CC,et al.Tumor-derived C-C motif ligand 2 (CCL2) induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment[J].Int J Radiat Oncol Biol Phys,2022 Jun 10:S0360-3016(22)00598-3.Epub ahead of print.[7]Lavender N,Yang J,Chen SC,et al.The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo[J].BMC Cancer,2017,17(1):88.[8]Balkwill F.Cancer and the chemokine network[J].Nat Rev Cancer,2004,4(7):540-550.[9]Yoshimura T,Yuhki N,Moore SK,et al.Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE[J].FEBS Lett,1989,244(2):487-493.[10]Kadomoto S,Izumi K,Mizokami A.Roles of CCL2-CCR2 Axis in the Tumor Microenvironment[J].Int J Mol Sci,2021,22(16):8530.[11]Liu H,Yang Z,Lu W,et al.Chemokines and chemokine receptors: A new strategy for breast cancer therapy[J].Cancer Med,2020,9(11):3786-3799.[12]Aerken M,Kouji I,Kazuyoshi S,et al.Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis[J].Oncotarget,2017,8(6):9739-9751.[13]Ding M,He SJ,Yang J.MCP-1/CCL2 Mediated by Autocrine Loop of PDGF-BB Promotes Invasion of Lung Cancer Cell by Recruitment of Macrophages Via CCL2-CCR2 Axis[J].J Interferon Cytokine Res,2019,39(4):224-232.[14]Zhuang H,Cao G,Kou C,et al.CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition invitro through activation of the Hedgehog pathway[J].Oncology Reports,2018,39(1):21-30.[15]Sanford DE,Belt BA,Panni RZ,et al.Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis[J].Clin Cancer Res,2013,19(13):3404-3415.[16]Chen CH,Su LJ,Tsai HT,et al.ELF-1 expression in nasopharyngeal carcinoma facilitates proliferation and metastasis of cancer cells via modulation of CCL2/CCR2 signaling[J].Cancer Manag Res,2019,11:5243-5254.[17]Wang Z,Xie H,Lin Z,et al.CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma[J].Oncotarget,2016,7(32):51525-51534.[18]Xu M,Wang Y,Xia R,et al.Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting[J].Cell Prolif,2021,54(10):e13115.[19]Yong VW.A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis[J].Carcinogenesis,2012,33(2):312-319.[20]陈雨蒙.肿瘤相关血管内皮细胞通过CCL2/CCR2促进单核细胞趋化增强M2型极化作用的研究[D].长春:吉林大学,2021.[21]Lindholm PF,Sivapurapu N,Jovanovic B,et al.Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-kappaB Activity[J].J Clin Cell Immunol,2015,6(2):308.[22]Li X,Yao W,Yuan Y,et al.Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma[J].Gut,2017,66(1):157-167.[23]Mohamed HT,El-Ghonaimy EA,El-Shinawi M,et al.IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2[J].Toxicol Appl Pharmacol,2020,401:115092.